1. Agomelatine improves memory and learning impairments in a rat model of LPS-induced neurotoxicity by modulating the ERK/SorLA/BDNF/TrkB pathway.
- Author
-
Abdelaziz M, Mohamed AF, Zaki HF, and Gad SS
- Subjects
- Rats, Animals, Brain-Derived Neurotrophic Factor metabolism, Amyloid Precursor Protein Secretases metabolism, Amyloid Precursor Protein Secretases pharmacology, MAP Kinase Signaling System, Amyloid beta-Peptides metabolism, Maze Learning, Aspartic Acid Endopeptidases metabolism, Aspartic Acid Endopeptidases pharmacology, Hippocampus, Memory Disorders chemically induced, Memory Disorders drug therapy, Memory Disorders metabolism, Lipopolysaccharides toxicity, Learning Disabilities metabolism, Learning Disabilities pathology
- Abstract
The mutual interplay between neuroinflammation, synaptic plasticity, and autophagy has piqued researchers' interest, particularly when it comes to linking their impact and relationship to cognitive deficits. Being able to reduce inflammation and apoptosis, melatonin has shown to have positive neuroprotective effects; that is why we thought to check the possible role of agomelatine (AGO) as a promising candidate that could have a positive impact on cognitive deficits. In the current study, AGO (40 mg/kg/day, p.o., 7 days) successfully ameliorated the cognitive and learning disabilities caused by lipopolysaccharide (LPS) in rats (250 μg/kg/day, i.p., 7 days). This positive impact was supported by improved histopathological findings and improved spatial memory as assessed using Morris water maze. AGO showed a strong ability to control BACE1 activity and to rein in the hippocampal amyloid beta (Aβ) deposition. Also, it improved neuronal survival, neuroplasticity, and neurogenesis by boosting BDNF levels and promoting its advantageous effects and by reinforcing the pTrkB expression. In addition, it upregulated the pre- and postsynaptic neuroplasticity biomarkers resembled in synapsin I, synaptophysin, and PSD-95. Furthermore, AGO showed a modulatory action on Sortilin-related receptor with A-type repeats (SorLA) pathway and adjusted autophagy. It is noteworthy that all of these actions were abolished by administering PD98059 a MEK/ERK pathway inhibitor (0.3 mg/kg/day, i.p., 7 days). In conclusion, AGO administration significantly improves memory and learning disabilities associated with LPS administration by modulating the ERK/SorLA/BDNF/TrkB signaling pathway parallel to its capacity to adjust the autophagic process., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF